Antithrombin is one of the main endogenous anticoagulants and its de®ciency is associated with deep venous thrombosis. The aim of the present study was to evaluate the prevalence of antithrombin de®ciency in patients with chronic lower extremity ulcers. Forty-eight patients with chronic lower limb ulcers for longer than 10 years, evaluated during 1997, were studied: 40 were female (83.3%) and eight were male (16.6%), with ages ranging from 43 to 73 years (mean, 55.2 years). Antithrombin was dosed by the coagulometric method, with evaluation of the functional activity. Measurement was repeated in those cases where de®ciency was found to be present. The highest prevalence rate for antithrombin de®ciency in the general population was one in every 2000 cases. Data analysis was performed by utilizing the odds ratio with a con®dence interval of 95% and P < 0.05. De®ciency in antithrombin levels was recorded in two (4.1%) of the patients with chronic ulcer. These results indicate a higher prevalence rate of antithrombin de®ciency in those patients with chronic leg ulcers, suggesting that an association may be present. Further studies with a larger number of patients are required to con®rm this hypothesis. Blood Coagul Fibrinolysis 12:593±595 # 2001 Lippincott Williams & Wilkins.
Introduction
Antithrombin is one of the major endogenous anticoagulant agents that inhibit ®brinogen conversion into ®brin in the coagulation cascade. It has been reported by Brinkhous et al. [1] , studied from a genetic and hereditary perspective by Egebert [2] and functionally demonstrated by Sas et al. [3] . The association of antithrombin de®ciency with thrombosis has been well de®ned. However, there is no established association with chronic leg ulcers.
Antithrombin de®ciency may result from hereditary or acquired factors, and develops by mechanisms that reduce synthesis or lead to dysfunction or through increased consumption or renal loss [4] .
Venous ulcers may result from several causes. A study of the general population found that 73% of the causes of ulcers result from venous problems, 8% from arterial problems, 3% by diabetes, 2% by traumatic injuries and 14% result from other etiologies [5] .
The prevalence of active venous ulcers in the adult population older than 18 years of age is about 0.3% and deep venous thrombosis is an important risk factor for the development of leg ulcers. The annual incidence in patients with previously existing venous thrombosis is 1±2% [6] . The combination of antithrombin de®ciency with deep venous thrombosis ranged from 0.5 to 8.0% in the literature [7] . The objective of the present study was to evaluate the prevalence of antithrombin de®ciency in patients with chronic leg ulcers for longer than 10 years and compare it with the prevalence of this de®ciency in the general population.
Materials and methods
Forty-eight patients with chronic ulcers were evaluated retrospectively; 40 (83.3%) were female and eight were male (16.6%), with age ranging from 43 to 73 years and a mean of 55.2 years. A routine phlebography was not performed; however, in 15 of the patients that had previously been submitted to one, the results were compatible with chronic venous insuf®ciency. The inclusion criteria were presence of venous ulcers for longer than 10 years, the presence of hyperpigmentation and dermato®brosis. Patients were excluded if a history of trauma, intermittent claudication or if ankle-brachial index (ABI) measurements less than 1 were present.
For laboratory assays, blood samples were collected into plastic syringes containing 3.8% (wt/vol) sodium citrate in a ratio of 0.1 : 0.99 (vol./vol.) anticoagulant to blood. Platelet-poor plasma was obtained by centrifugation at 2000 3 g for 20 min and stored at À808C until it was analyzed. Antithrombin activity was measured using Berichrom ATIII (Behringwerke, Marbug, Germany). The reference values used for antithrombin activity were 80±120%.
Measurement was repeated in those cases where de®ciency was found to be present. The highest prevalence rate for antithrombin de®ciency reported in the available medical literature for the general population was one in every 2000 cases.
Statistical analysis of the data was performed by utilizing the odds ratio with a con®dence interval (CI) of 95% and P , 0.05.
Results
Of the 48 patients with chronic ulcers, antithrombin de®ciency was observed in two (4.1%) patients. As previously mentioned, the highest prevalence rate detected in the general population and reported in the literature is one in 2000. The calculated odds ratio between the studied group and the general population was 86.91, with a 95% CI of 7.74± 975.68 (P , 0.05).
Discussion
The prevalence of antithrombin de®ciency (4.1%) in patients with chronic lower limb ulcers was statistically signi®cant when compared with the prevalence data in a study in the general population ranging from one for every 2000 to one for every 5000 inhabitants [7] . Despite the fact that the data in the literature does not constitute an ideal control group, it does however provide us with an acceptable estimate. This result was similar to that observed in individuals with deep venous thrombosis found in the literature (0.5±8%) [7] and in our service (3.4%).
A local population control group would be ideal;
however, this investigation would not be feasible due to the costs involved. The major chronic complication of deep venous thrombosis is lower extremity ulcer. Patients with deep venous thrombosis combined with antithrombin de®ciency may develop lower extremity ulcer. One of the characteristics of the thromboembolic events in patients with antithrombin de®ciency is its occurrence in individuals with ages ranging from 16 to 19 years [7] , leading patients 30±40 years old to develop venous ulcers. Another characteristic is the new thrombotic events that these patients tend to develop during their lifetimes. The questioning should reside on the degree of venous obstruction that these thrombotic events may cause, especially in those cases of proximal thrombosis. Several issues stem from this supposition.
Should not the increased likelihood and occurrence of new thrombotic episodes cause more severe sequelae to these patients? Since it is known that the main complication during the acute phase of deep venous thrombosis is pulmonary embolus and that during the chronic phase is chronic venous insuf®ciency, one may speculate that the prevention of these new thrombotic episodes might protect these patients from more severe cases of chronic venous insuf®ciency.
The literature has not valued these more chronic aspects of the thrombophilias, concentrating mainly on the acute thrombotic episodes.
The thrombophilias are also associated with an increased incidence of arterial thrombosis, this may also contribute to worsen the prognosis of these patients. Another aspect that needs to be considered is whether healing of these ulcers is the same as in those patients without thrombophilias.
In the present article, we exclude patients with arterial disease by history and ABI measurements. However, during the follow-up of patients with other thrombophilias (anticardiolipin antibodies and protein-S de®ciency) and ulcerative lesions, we observed the occurrence of arterial thrombosis. The small number of patients with antithrombin de®ciency and ulcerative lesions precludes a more conclusive study at the moment. Phlebography would be an important adjunct to verify the presence of previous thrombotic events in all of our patients. Our decision to not perform it was due to its invasiveness, and at the time we did not have a duplex scan available. The clinical aspect in the patients with longer than 10 years of ulcers was very suggestive of chronic venous insuf®ciency; however, in those patients with antithrombin de®ciency, the presence of previous deep vein thrombosis was veri®ed by phlebography. Antithrombin de®ciency was always con®rmed on two separate occasions and, while screening of the family members has not yet been performed, a positive family history of thrombosis is present in all cases. Acquired antithrombin de®ciencies are usually observed in patients with acute thrombosis, disseminated intravascular coagulopathies, liver diseases and multiple traumas. Patients with these alterations were therefore excluded, favoring a congenital etiology.
A literature search did not reveal any data showing a correlation between the prevalence of antithrombin de®ciency and chronic ulcers. Further studies are necessary to con®rm these ®ndings.
Conclusion
The prevalence of antithrombin de®ciency (4.1%) in patients with chronic leg ulcers is signi®cantly higher than that in the general population. There is a statistically signi®cant association between antithrombin de®ciency and chronic leg ulcers. Antithrombin de®ciency may be a risk factor for chronic venous ulcer and should be routinely investigated.
Further studies should address the issue of chronic complications of these thrombophilias.
